Investing in biotech stocks without any drugs on the market can be scary. These suggestions can help you make money in this high-risk sector.
Compare NVAX Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Novavax
A hugely disappointing quarter and new bear takes on the company by analysts made for a very bad set of trading days.
Believe it or not, Novavax's revenue could decline and still cause the stock to soar.
As a result of some bad news, the market might be underestimating its chances of a comeback.
The vaccine maker reported dismal Q2 results with a bleaker outlook for the rest of the year.
Sales of Novavax's COVID-19 vaccine won't be anywhere close to earlier projections.
Investors sold out of the company after it fell short with second-quarter results.
The biotech company got good news about its COVID-19 vaccine.
A lot is riding on how effectively it can penetrate the market for coronavirus booster shots.
Novavax offers several clear advantages over its larger rival.